Saniona AB (SE:SANION)
:SANION
Want to see SE:SANION full AI Analyst Report?
SANION Stock Chart & Stats
kr21.10
-kr0.15(-2.06%)
At close: 4:00 PM EST
kr21.10
-kr0.15(-2.06%)
Day’s Range― - ―
52-Week Rangekr8.03 - kr28.30
Previous CloseN/A
Volume191.43K
Average Volume (3M)1.06M
Market Cap
kr1.94B
Enterprise Valuekr1.57B
Total Cash (Recent Filing)kr531.98M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)8.7
Beta-0.09
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure in 2025 and TTM materially reduces financial fragility and interest burden, giving management flexibility to fund R&D, tolerate lumpy clinical milestones, and pursue partnerships without near-term refinancing risk. This supports multi-quarter durability in operations and strategic options even if revenues fluctuate.
Positive Cash GenerationCash-backed earnings with positive operating and free cash flow—and FCF covering ~73% of net income—indicate current profitability is supported by real cash generation. That strengthens the firm's ability to self-fund development, weather short-term revenue gaps, and lowers reliance on markets for financing across the next several quarters.
Very High Profitability MarginsExtremely high TTM gross, operating and net margins imply the business can convert incremental revenue into substantial earnings, supporting internal funding of programs and improving resilience to cost pressures. Sustained margins provide structural buffer for reinvestment in trials and partnerships over a multi-month horizon.
Bears Say
Revenue VolatilityA sharp TTM revenue decline after a 2024 surge signals uneven top-line timing and reliance on episodic events or milestone receipts. Such volatility impairs multi-quarter planning, makes budgeting for clinical programs and headcount harder, and increases the chance of needing external financing when milestone timing slips.
Historical Balance Sheet InstabilityPrior negative equity and heavy leverage in 2023 show the company has been through periods of financial strain, reducing confidence that current strength is permanent. This history raises the risk of rapid balance sheet deterioration if cash flows reverse, and can affect partner or investor willingness to commit capital long-term.
Past Cash Burn And Weak FCF GrowthMulti-year cash burn followed by negative free cash flow growth in the TTM period indicates cash generation durability is uncertain. If development timelines lengthen or revenues decline, past burn patterns suggest the firm may again require external funding, which could dilute shareholders or constrain program investment.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr8.03 and its highest was kr28.30 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.94B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Aug 27, 2026 which is in 84 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on May 26, 2026. The company reported -kr0.334 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.334.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.334 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.884%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---